4.9Industry

Pharmacy & Life Sciences

CROs, CDMOs, specialty pharmaceutical manufacturers, diagnostic labs, and pharmacy benefit managers supporting the drug development and distribution continuum.

8
Segments
33
Verticals

Overview

Pharmacy & Life Sciences spans the drug value chain — biopharmaceutical manufacturing, retail and specialty pharmacy, pharmacy benefit management, clinical research and contract manufacturing, laboratory and diagnostic services, and life-sciences services. It is one of the largest and most strategically important parts of healthcare.

Biopharma M&A is driven by patent cliffs and the GLP-1 boom; the PBM oligopoly is under intense regulatory and political scrutiny over drug pricing; retail pharmacy is consolidated and financially stressed; and CRO/CDMO outsourcing is booming with drug-development demand. Note that revenue overlaps across the chain — the same drug is counted at manufacturing, PBM, and retail stages — so segment figures are not additive.

Market snapshot

Companies
~68,000
FragmentationConsolidating

U.S. Census Bureau 2022 CBP/Economic Census across biopharma (325411/412/414, ~$211B), PBM (524292, ~$284B), retail pharmacy (456110, ~$544B), and labs (621511/991, ~$76B). Figures overlap across the value chain and are not summed; establishment count is additive.

Business model & economics

Revenue model
Drug sales, dispensing margin, benefit management, and services
Recurring revenue
High — recurring prescriptions and services
EBITDA margin
Varies widely — high for branded pharma, thin for pharmacy
Capex intensity
High
  • Patent cliffs and GLP-1 drive biopharma M&A.
  • PBM oligopoly under intense regulatory scrutiny.
  • CRO/CDMO outsourcing booming with drug-development demand.

M&A deal context

High deal activity

Who’s acquiring

Big pharma & biopharma strategicsCRO/CDMO consolidatorsPharmacy, PBM & payer integrators

What’s driving deals

  • Patent-cliff-driven biopharma acquisition.
  • CRO/CDMO outsourcing consolidation.
  • PBM and pharmacy vertical integration and scrutiny.

Segment classifications

Find Pharmacy & Life Sciences acquisition targets

Search Acquisera’s index for companies classified under Pharmacy & Life Sciences (4.9) and build a targeted deal pipeline.

Search companies